The privately-held biotech company focuses on blocking specific parts of the immune system involved in disease processes. With a portfolio of neutralizing monoclonal antibodies, NovelMed targets acute and chronic diseases with large market potential and unmet medical needs. Their complement-based therapies have the potential for better safety and efficacy profiles compared to existing drugs. The company's pipeline includes therapeutic antibodies for diseases such as paroxysmal nocturnal hemoglobinuria (PNH), arthritis, macular degeneration, osteoarthritis, ischemia, and surgical adhesions. NovelMed has generated pre-clinical data and accumulated significant intellectual property for their humanized antibody platform, positioning them as an exciting player in the biotech industry.